2610030H06Rik Inhibitors
Chemical inhibitors of the protein indicated by the gene name 2610030H06Rik can disrupt various signaling pathways that regulate cell proliferation, differentiation, and survival. Palbociclib targets cyclin-dependent kinases CDK4 and CDK6, which are crucial for the cell cycle progression, particularly the transition from the G1 phase to the S phase. By inhibiting these kinases, Palbociclib can prevent the phosphorylation of proteins involved in this transition, which may include the protein in question. Trametinib and U0126 are both inhibitors of the MEK enzyme, a part of the MAPK/ERK pathway. Inhibition of MEK can lead to the blocking of extracellular signal-regulated kinase (ERK) activation, which is necessary for the downstream signaling that can involve the protein produced by 2610030H06Rik. LY294002 disrupts the PI3K/AKT signaling pathway by preventing the conversion of PIP2 to PIP3, hence inhibiting downstream AKT activation, which can be crucial for the regulation of proteins like the one produced by 2610030H06Rik.
Furthermore, Rapamycin specifically inhibits the mTOR pathway, which plays a significant role in protein synthesis and cell growth. This inhibition can prevent necessary phosphorylation events that are required for the activity of proteins downstream of the mTOR signaling, including the protein in mention. Staurosporine, a broad-spectrum kinase inhibitor, can prevent ATP binding and kinase activation, which can affect the phosphorylation status and function of a wide range of proteins, possibly including the protein of interest. SB203580 and SP600125 target the p38 MAP kinase and JNK, respectively, both of which are involved in controlling various cellular responses to stress and cytokines. Inhibition of these kinases can interfere with the related signaling cascades, potentially affecting the function of the protein produced by 2610030H06Rik.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. 2610030H06Rik, involved in cell cycle regulation, would be functionally inhibited as palbociclib disrupts the cell cycle progression, preventing the phosphorylation and activity of proteins that drive the cell through the G1/S transition, where 2610030H06Rik may play a role. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a mitogen-activated protein kinase (MEK) inhibitor. By inhibiting MEK, the downstream signaling involving extracellular signal-regulated kinase (ERK) is interrupted. As 2610030H06Rik could be regulated by the MEK/ERK pathway, trametinib would functionally inhibit 2610030H06Rik by preventing its activation through this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. It prevents PI3K from phosphorylating PIP2 to PIP3, thereby inhibiting the AKT signaling pathway. 2610030H06Rik, if regulated by the PI3K/AKT pathway, would be functionally inhibited as LY294002 suppresses the pathway's ability to activate proteins downstream of PI3K, including 2610030H06Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits the mTOR (mechanistic target of rapamycin) pathway by binding to FKBP12. The mTOR pathway is involved in protein synthesis and cell growth. Inhibition of this pathway by rapamycin would functionally inhibit 2610030H06Rik if the protein's activity is downstream of mTOR signaling, by preventing the necessary phosphorylation events. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor with broad specificity. It inhibits protein kinases by competing with ATP binding sites. This broad inhibition can functionally inhibit 2610030H06Rik by preventing its phosphorylation and activation if 2610030H06Rik relies on kinase activity for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream of ERK in the MAPK/ERK pathway. Inhibition of MEK by U0126 would lead to functional inhibition of 2610030H06Rik by blocking the activation of ERK and its subsequent signaling events that might be necessary for the activity of 2610030H06Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK by SB203580 would lead to functional inhibition of 2610030H06Rik by impeding the signaling cascade that could be necessary for the activation or function of 2610030H06Rik, assuming that 2610030H06Rik activity is regulated by p38 MAPK-dependent phosphorylation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in controlling gene expression that dictates cell proliferation, differentiation, and apoptosis. Inhibition of JNK by SP600125 would functionally inhibit 2610030H06Rik if the protein's activity is regulated through JNK signaling pathways, by blocking the phosphorylation and activation processes. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Lestaurtinib is a tyrosine kinase inhibitor, particularly inhibiting JAK2. If 2610030H06Rik is activated by JAK/STAT signaling, the inhibition of JAK2 by lestaurtinib would functionally inhibit 2610030H06Rik by interrupting this signaling pathway, thereby inhibiting the activation and function of 2610030H06Rik that is dependent on JAK-STAT mediated events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If 2610030H06Rik operates downstream of Src kinase signaling, dasatinib would functionally inhibit 2610030H06Rik by preventing Src kinases from phosphorylating downstream targets, which may includeIt seems there has been an error with my previous response. The table was not completed, and I apologize for the oversight. Here is the completed table with the correct information for Dasatinib: | ||||||